Neoadjuvant Weekly Paclitaxel and Carboplatin with Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: A Brown University Oncology Research Group (BrUOG) Study [post]

Mary Lorraine Lopresti, Jessica J Bian, Bachir Joseph Sakr, Rochelle S Strenger, Robert Duffy Legare, Mary Anne Fenton, Sabrina M Witherby, Donald S Dizon, Sonali V Pandya, Ashley R Stuckey, David A Edmondson, Jennifer S Gass (+5 others)
2021 unpublished
Purpose: In HER2-positive breast cancer (HER2+BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates. Anthracycline-free NACT regimens avoid toxicities associated with anthracyclines, but every 3-week TCHP also has substantial side effects. We hypothesized that a weekly regimen might have equivalent efficacy with less toxicity; we also investigated whether poorly responding patients would benefit from switching to AC.
more » ... ing to AC. Methods:Patients with clinical stage II-III HER2+BC received weekly paclitaxel 80 mg/m2 and carboplatin AUC2 with every 3-week trastuzumab and pertuzumab (wPCbTP), with the option of splitting the pertuzumab loading dose. After 12 weeks, responding patients continued wPCbTP for another 6 weeks, while non-responders switched to AC. Dose modifications and post-op therapy were at investigator discretion. Results:In 30 evaluable patients, the pCR rate was 77% (95% CI 58-90%); 12/14 (86%) in ER-negative and 11/16 (69%) in ER-positive. Only two patients transitioned to AC for non-response, of which one achieved pCR. There were no episodes of febrile neutropenia or grade >3 peripheral neuropathy, though several patients who continued wPCbTP stopped before week 18. Split-dose pertuzumab was associated with less grade >2 diarrhea (40%) than the standard loading dose (60%). Conclusions:pCR rates with our regimen were as high as reported with TCHP with fewer grade >3 toxicities, though diarrhea remains a concern. Too few patients had a suboptimal response to adequately test switching to AC. The wPCbTP regimen should be considered an alternative to TCHP as neoadjuvant therapy for HER2+BC.ClinicalTrials.gov identifier: NCT02789657
doi:10.21203/rs.3.rs-346637/v1 fatcat:r3sfk7ggv5biridbbabazlilem